The DREADD agonist clozapine N-oxide (CNO) is reverse-metabolized to clozapine and produces clozapine-like interoceptive stimulus effects in rats and mice

Clozapine-N-oxide (CNO) has long been the ligand of choice for selectively activating Designer Receptors Exclusively Activated by Designer Drugs (DREADDs). However, recent studies have challenged the long-held assertion that CNO is otherwise pharmacologically inert. The present study aimed to 1) det...

Descripción completa

Detalles Bibliográficos
Autores principales: Manvich, Daniel F., Webster, Kevin A., Foster, Stephanie L., Farrell, Martilias S., Ritchie, James C., Porter, Joseph H., Weinshenker, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5832819/
https://www.ncbi.nlm.nih.gov/pubmed/29497149
http://dx.doi.org/10.1038/s41598-018-22116-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5832819/
https://www.ncbi.nlm.nih.gov/pubmed/29497149
http://dx.doi.org/10.1038/s41598-018-22116-z

Ejemplares similares